Answers are grounded in this paper and cite their sources.
Reveals that parthenolide attenuates hypoxia-induced pulmonary hypertension by inhibiting STAT3 signaling, highlighting a therapeutic strategy against vascular remodeling.
Pulmonary hypertension (PH) is a chronic lung disease characterized by the progressive pulmonary vascular remodeling with increased pulmonary arterial pressure and right ventricular failure. Pulmonary vascular remodeling involves the proliferation, migration, and resistance to apoptosis of pulmonary artery smooth cells (PASMCs). Parthenolide (PTN) is a bioactive compound derived from a traditional medical plant feverfew (Tanacetum parthenium), and it has been studied for treatment of pulmonary fibrosis, lung cancer, and other related ailments. However, the function of PTN in the treatment of PH has not been studied.
No takes yet. Share an insight, caveat, or question.
Yao et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: